Last updated: May 6, 2025
Sponsor: Alexandria University
Overall Status: Active - Recruiting
Phase
1/2
Condition
N/ATreatment
Dexmedetomidine infusion
paragastric autonomic neural block
Clinical Study ID
NCT06970678
16/463
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
ASA II-III
18-60 years
BMI of 35-50 kg/m²
Exclusion
Exclusion Criteria:
Patients with chronic pain disorders
Patients using gabapentin, chronic opioid users
Patients on anticoagulant therapy
Patients with history of upper gastrointestinal system surgery
Patients with liver, kidney, cardiovascular diseases
Patients with allergy to dexmedetomidine or bupivacaine
Study Design
Total Participants: 46
Treatment Group(s): 2
Primary Treatment: Dexmedetomidine infusion
Phase: 1/2
Study Start date:
April 04, 2025
Estimated Completion Date:
June 18, 2025
Connect with a study center
Alexandria Main University Hospital
Alexandria,
EgyptActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.